Latest results FY2025 · Prices updated Oct 30, 2026
HQ: Chiyoda, TokyoFounded 2008183 employeesWebsite
Operates two main segments: Medical (pharmaceuticals) and Nutraceuticals (consumer health products). A leader in psychiatric treatments and iconic health brands like Pocari Sweat.
Business segments (share of revenue)
Latest results
FY2025
vs. same period a year earlier
Company forecastFY2026
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Pharmaceutical Products and Services | 71% | ¥1.7T | ¥445.3B | 25.5% |
| Nutraceuticals and Health Products | 23% | ¥577.7B | ¥57.7B | 10.0% |
| Other Business Operations | 5% | ¥115.9B | ¥8.0B | 6.9% |
| Consumer Healthcare Business | 1% | ¥34.6B | ¥25.1B | 72.6% |
Close (Oct 30, 2026)
¥12,015+48.2% (1Y)
Otsuka +48.2% over 1Y, 37.0pt above the industry average (23 companies, +11.2%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2025FY | ¥2.5T | ¥479.4B | ¥363.1B | ¥4.2T | +6.0% |
| 2024FY | ¥2.3T | ¥323.6B | ¥347.3B | ¥3.7T | +15.4% |
| 2023FY | ¥2.0T | ¥139.6B | ¥121.6B | ¥3.4T | +16.1% |
| 2022FY | ¥1.7T | ¥150.3B | ¥133.9B | ¥3.1T | +16.0% |
| 2021FY | ¥1.5T | ¥154.5B | ¥125.5B | ¥2.8T | — |
Sources: annual securities reports, earnings releases and other public disclosures (Dec 2024)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
